Payment overview · 2025
General Payments
$956.69
68 reported records · 20 companies
Healthcare provider profile · identity verified
Mark Anthony Yackley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUTCHINSON, KS · NPI 1356347215
Verified facts
What the public records show
CMS Open Payments records show Mark Anthony Yackley, M.D. received $956.69 in general payments during 2025 across 68 reported records.
Novo Nordisk Inc accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Kerendia, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $249.79 | 26.1% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $169.34 | 17.7% | 17 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $97.17 | 10.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.68 | 6.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.66 | 6.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.28 | 4.4% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.10 | 3.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.99 | 3.0% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $26.03 | 2.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.68 | 2.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.60 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.57 | 1.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.13 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.03 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.98 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.07 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.98 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.32 | 1.5% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $14.14 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $956.69 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $212.38 | 16 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $179.21 | 14 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $107.70 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $63.66 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.64 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.64 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.68 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.12 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $42.28 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 975 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 950 | 209 |
| Losartan Potassium | Losartan Potassium | 924 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 813 | 179 |
| Gabapentin | Gabapentin | 703 | 121 |
| Omeprazole | Omeprazole | 629 | 151 |
| Furosemide | Furosemide | 563 | 123 |
| Potassium Chloride | Potassium Chloride | 551 | 101 |
| Lisinopril | Lisinopril | 547 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 547 | 122 |
| Simvastatin | Simvastatin | 474 | 111 |
| Metformin Hcl | Metformin Hcl | 426 | 98 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 417 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 394 | 99 |
| Alprazolam | Alprazolam | 330 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 327 | 62 |
| Meloxicam | Meloxicam | 323 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 79 |
| Sertraline Hcl | Sertraline Hcl | 300 | 62 |
| Finasteride | Finasteride | 291 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 284 | 62 |
| Montelukast Sodium | Montelukast Sodium | 281 | 60 |
| Atenolol | Atenolol | 248 | 57 |
| Prednisone | Prednisone | 241 | 149 |
| Glimepiride | Glimepiride | 230 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 55 |
| Trazodone Hcl | Trazodone Hcl | 221 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 206 | 39 |
| Donepezil Hcl | Donepezil Hcl | 201 | 42 |
| Eliquis | Apixaban | 200 | 31 |
| Warfarin Sodium | Warfarin Sodium | 197 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 46 |
| Allopurinol | Allopurinol | 176 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 46 |
| Buspirone Hcl | Buspirone Hcl | 172 | 32 |
| Ozempic | Semaglutide | 164 | 26 |
| Estradiol | Estradiol | 155 | 34 |
| Alendronate Sodium | Alendronate Sodium | 151 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 150 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 147 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 147 | 24 |
| Carvedilol | Carvedilol | 139 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 26 |
| Famotidine | Famotidine | 135 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 36 |
| Memantine Hcl | Memantine Hcl | 127 | 20 |
| Amoxicillin | Amoxicillin | 123 | 93 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 11 |
| Levetiracetam | Levetiracetam | 117 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 21 |
| Spironolactone | Spironolactone | 116 | 29 |
| Aripiprazole | Aripiprazole | 114 | 19 |
| Tramadol Hcl | Tramadol Hcl | 113 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 17 |
| Terazosin Hcl | Terazosin Hcl | 107 | 21 |
| Azithromycin | Azithromycin | 104 | 81 |
| Clonazepam | Clonazepam | 104 | 16 |
| Nystatin | Nystatin | 98 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 84 |
| Jardiance | Empagliflozin | 96 | 19 |
| Pregabalin | Pregabalin | 93 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | 13 |
| Propranolol Hcl | Propranolol Hcl | 89 | 15 |
| Synthroid | Levothyroxine Sodium | 89 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 87 | 19 |
| Januvia | Sitagliptin Phosphate | 86 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 22 |
| Levofloxacin | Levofloxacin | 85 | 77 |
| Mounjaro | Tirzepatide | 85 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | 19 |
| Fluconazole | Fluconazole | 83 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 12 |
| Topiramate | Topiramate | 82 | 17 |
| Gemtesa | Vibegron | 80 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 20 |
| Mirtazapine | Mirtazapine | 78 | 21 |
| Bupropion Xl | Bupropion Hcl | 76 | 14 |
| Celecoxib | Celecoxib | 74 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 64 |
| Irbesartan | Irbesartan | 71 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 20 |
| Methenamine Hippurate | Methenamine Hippurate | 70 | 17 |
| Baclofen | Baclofen | 69 | 26 |
| Ondansetron Odt | Ondansetron | 69 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | 11 |
| Cephalexin | Cephalexin | 68 | 50 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 13 |
| Ezetimibe | Ezetimibe | 67 | 16 |
| Lorazepam | Lorazepam | 67 | 14 |
| Novolog Flexpen | Insulin Aspart | 67 | 16 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 22 |
| Primidone | Primidone | 64 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 62 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 14 |
| Lovastatin | Lovastatin | 60 | 15 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Fenofibrate | Fenofibrate | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 40 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 40 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Fentanyl | Fentanyl | 50 | suppressed |
| Bumetanide | Bumetanide | 49 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 46 | 11 |
| Sotalol | Sotalol Hcl | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Glipizide | Glipizide | 43 | 12 |
| Metronidazole | Metronidazole | 43 | 39 |
| Doxepin Hcl | Doxepin Hcl | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Diazepam | Diazepam | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 12 |
| Minoxidil | Minoxidil | 39 | suppressed |
| Acyclovir | Acyclovir | 38 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 14 |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 12 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 29 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 11 |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Xeljanz Xr | Tofacitinib Citrate | 27 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Metolazone | Metolazone | 24 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Armour Thyroid | Thyroid,pork | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Famciclovir | Famciclovir | 19 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 13 |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 11 |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Cabergoline | Cabergoline | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $956.69 · 68 records | Novo Nordisk Inc | AREXVY, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, INJECTAFER, INSPIRE, Kerendia, LEQVIO, MOUNJARO, OPSUMIT, OTEZLA, Ozempic, Quviviq, REPATHA, REXULTI, Rybelsus, SHINGRIX, Tymlos, UPTRAVI, VOQUEZNA, Veozah, XIFAXAN, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error